Humana (NYSE:HUM) Price Target Raised to $300.00

Humana (NYSE:HUM - Free Report) had its price objective lifted by Robert W. Baird from $270.00 to $300.00 in a report released on Tuesday morning,Benzinga reports. They currently have a neutral rating on the insurance provider's stock.

HUM has been the subject of a number of other reports. Guggenheim started coverage on shares of Humana in a research note on Wednesday, April 9th. They set a "buy" rating and a $326.00 price target for the company. StockNews.com raised Humana from a "hold" rating to a "buy" rating in a research note on Monday, April 7th. Barclays increased their target price on Humana from $270.00 to $322.00 and gave the stock an "equal weight" rating in a research note on Friday, April 11th. JPMorgan Chase & Co. reduced their price target on shares of Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 18th. Finally, Truist Financial raised their target price on shares of Humana from $290.00 to $325.00 and gave the stock a "hold" rating in a research report on Friday, April 11th. Seventeen analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $284.90.

Humana Price Performance

Shares of NYSE:HUM traded down $21.20 during mid-day trading on Tuesday, reaching $264.41. The stock had a trading volume of 3,670,273 shares, compared to its average volume of 1,759,722. The business's 50 day moving average price is $265.90 and its 200 day moving average price is $270.03. Humana has a 1 year low of $213.31 and a 1 year high of $406.46. The company has a market cap of $31.91 billion, a P/E ratio of 26.57, a price-to-earnings-growth ratio of 2.05 and a beta of 0.62. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Research analysts expect that Humana will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.34%. Humana's dividend payout ratio (DPR) is presently 35.58%.

Hedge Funds Weigh In On Humana

Institutional investors and hedge funds have recently bought and sold shares of the company. FPC Investment Advisory Inc. purchased a new stake in Humana during the fourth quarter worth about $27,000. Centricity Wealth Management LLC purchased a new stake in shares of Humana during the fourth quarter worth $30,000. LFA Lugano Financial Advisors SA raised its stake in shares of Humana by 56.3% in the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock valued at $32,000 after acquiring an additional 45 shares in the last quarter. OFI Invest Asset Management acquired a new position in Humana during the 4th quarter worth $33,000. Finally, Riverview Trust Co purchased a new position in shares of Humana in the 1st quarter valued at about $34,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.